Drug Approval | April 12, 2025
FDA approves Opdivo plus Yervoy as treatment metastatic colorectal cancer
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
Prior to joining Eris, Ranganathan was Commercial Director, Women's Health, Metabolics, and International Business at Abbott India Limited
The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for metastatic breast cancer patients.
BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation
Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030
Prithwish has close to 28 years of experience in a Commercial role
IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy
Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Bumetanide Injection USP (RLD Bumex) had estimated annual sales of USD 20 million in the U.S.
Subscribe To Our Newsletter & Stay Updated
